Phio Pharmaceuticals Presents Positive Data On PH-894 Demonstrating Antitumor Efficacy In Model Of PD-1 Refractory Disease At AACR Annual Meeting 2022
hio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today